1
|
Montori M, Martini F, DE Blasio F, Buono T, Quatraccioni C, Guardati P, Calzolari M, Rossi C, Bendia E, Menzo S, Valenza C, Pellicano R, Maroni L, Benedetti A. Serological response after anti-SARS-CoV-2 BNT162b2 vaccine in IBD patients on biological therapy: a monocentric case-control study. Minerva Gastroenterol (Torino) 2023; 69:268-276. [PMID: 36255283 DOI: 10.23736/s2724-5985.22.03134-5] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 05/17/2023]
Abstract
BACKGROUND Inflammatory bowel disease (IBD) patients on biological therapy are receiving vaccines against severe acute respiratory syndrome Coronavirus 2 (SARS-CoV-2). However, it is unclear if IBD therapy could influence the response to this vaccine. In a case-control study, we assessed the antibody profiling after anti-SARS-CoV-2 BNT162b2 vaccine in IBD patients on biological therapy. METHODS We analyzed seroprevalence and antibody titer, after 14 weeks from the first BNT162b2 vaccine dose, in IBD patients on biological therapy and health care workers (HCWs). In IBD patients, medical history and disease data were recorded. RESULTS Eighty-two subjects were enrolled in this study. Among them, 40 were IBD patients on biological therapy and 42 were HCWs. All subjects developed an IgG anti-Spike antibody titer above the cut-off. IBD patients on biological therapy developed a lower antibody titer than HCWs (P<0.00001). No differences were reported in patients who received at least one dose of the vaccine within a period of 7 days from the last biological drug administration, compared to all other IBD patients. A difference was found between patients who were on concomitant immunosuppressive therapy and patients on sole biological therapy (P=0.0287). Patients with presence of any sign of disease activity (clinical, endoscopic or laboratory) showed a higher development of antibody titer compared to those in complete disease remission (P=0.0468). CONCLUSIONS Our data indicate that in IBD patients, treatment with biological therapies do not affect the seroprevalence but leads to a lower antibody titer development after anti-SARS-CoV-2 BNT162b2 vaccine.
Collapse
Affiliation(s)
- Michele Montori
- Clinic of Gastroenterology, Hepatology and Emergency Digestive Endoscopy, Ospedali Riuniti di Ancona, Ancona, Italy -
| | - Francesco Martini
- Clinic of Gastroenterology, Hepatology and Emergency Digestive Endoscopy, Ospedali Riuniti di Ancona, Ancona, Italy
| | - Federico DE Blasio
- Clinic of Gastroenterology, Hepatology and Emergency Digestive Endoscopy, Ospedali Riuniti di Ancona, Ancona, Italy
| | - Tiziana Buono
- Clinic of Gastroenterology, Hepatology and Emergency Digestive Endoscopy, Ospedali Riuniti di Ancona, Ancona, Italy
| | - Claudia Quatraccioni
- Clinic of Gastroenterology, Hepatology and Emergency Digestive Endoscopy, Ospedali Riuniti di Ancona, Ancona, Italy
| | - Paola Guardati
- Clinic of Gastroenterology, Hepatology and Emergency Digestive Endoscopy, Ospedali Riuniti di Ancona, Ancona, Italy
| | - Manuela Calzolari
- Clinic of Gastroenterology, Hepatology and Emergency Digestive Endoscopy, Ospedali Riuniti di Ancona, Ancona, Italy
| | - Chiara Rossi
- Clinic of Gastroenterology, Hepatology and Emergency Digestive Endoscopy, Ospedali Riuniti di Ancona, Ancona, Italy
| | - Emanuele Bendia
- Department of Digestive System Diseases, Digestive Endoscopy and Chronic Inflammatory Bowel Diseases, Ospedali Riuniti di Ancona, Ancona, Italy
| | - Stefano Menzo
- Department of Oncology and Hemato-Oncology, University of Milan, Milan, Italy
| | - Carmine Valenza
- Division of New Drugs and Early Drug Development for Innovative Therapies, European Institute of Oncology IRCCS, Milan, Italy
| | | | - Luca Maroni
- Clinic of Gastroenterology, Hepatology and Emergency Digestive Endoscopy, Ospedali Riuniti di Ancona, Ancona, Italy
| | - Antonio Benedetti
- Clinic of Gastroenterology, Hepatology and Emergency Digestive Endoscopy, Ospedali Riuniti di Ancona, Ancona, Italy
| |
Collapse
|
2
|
DE Blasio F. Probiotics and osteoarthritis in rats: how to translate these data in human setting? Panminerva Med 2020; 63:379. [PMID: 32759913 DOI: 10.23736/s0031-0808.20.04054-9] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/08/2022]
Affiliation(s)
- Federico DE Blasio
- Department of Gastroenterology and Transplantation, Clinic of Gastroenterology, Ospedali Riuniti di Ancona, Marche Polytechnic University, Ancona, Italy -
| |
Collapse
|